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The main component of plasma medicine is the use of low-temperature plasma (LTP) as a powerful tool for 
biomedical applications. LTP generates high reactivity at low temperatures and can be activated with noble gases 
with molecular mixtures or compressed air. LTP reactive species are quickly produced, and are a remarkably 
good source of reactive oxygen and nitrogen species including singlet oxygen (O2), ozone (O3), hydroxyl radicals 
(OH), nitrous oxide (NO), and nitrogen dioxide (NO2). Its low gas temperature and highly reactive non- 
equilibrium chemistry make it appropriate for the alteration of inorganic surfaces and delicate biological sys-
tems. Treatment of oral biofilm-related infections, treatment of wounds and skin diseases, assistance in cancer 
treatment, treatment of viruses’ infections (e.g. herpes simplex), and optimization of implants surfaces are 
included among the extensive plasma medicine applications. Each of these applications will be discussed in this 
review article.   
1. Introduction 
Low-temperature plasma (LTP) applications in biomedical systems 
are the main element of plasma medicine [1]. This interdisciplinary field 
of research has been increasingly attracting scientific attention [2]. 
Physical plasma is generally produced by combining high temperature 
or electromagnetic field power to a neutral gas so the ionized gaseous 
substance becomes gradually electrically conductive [3]. LTP jets are 
currently the concentration of plasma research. LTP jets can generate 
high reactivity at low gas temperatures and can work with noble gases 
with molecular mixtures or with compressed air. LTP’s low temperature 
(below 40 C) and highly reactive non-equilibrium chemistry make it 
appropriate for the modification of inorganic surfaces in addition to 
treatment of delicate biological systems [4]. 
Plasmas produce electromagnetic radiation, including ultra-violet 
(UV) radiation and light in the visible spectrum, and involves excited 
gas particles, charged ions, free electrons, free radicals, neutral reactive 
oxygen and nitrogen species (ROS/RNS), and molecule fragments. LTP is 
known as the fourth state of matter, along with solid, fluid, and gaseous, 
considering its unique features when compared to neutral gases [3]. 
Hence, because of its distinct characteristics, plasma has been used for 
surface applications in industry [5]. Plasma uses vary from cleaning of 
microelectronics’ surfaces [4], surface activation for enhanced adhesion 
of paint and glue [4], and to enhance contrast for microscopy images, 
such as for scanning electron microscopy [6]. The low temperature 
permits treating polymers, and the design of some plasma equipment 
allow it to penetrate challenging cavities, which was verified in a stack 
of polymer discs with openings that shaped a winding cavity [7]. Plasma 
technology has also been used for the deposit of films containing zinc, 
using a solution of zinc nitrate hexahydrate salt in water as a source of 
zinc [8]. The industrial application of plasma processes for medical 
devices has been extensively demonstrated [9,10]. For example, 
argon-based non-thermal plasma jet guided by radio frequency (27.12 
MHz), which was applied as an antimicrobial therapy on medical de-
vices that were made out of high-temperature susceptible material. This 
plasma was effective on eradicating Bacillus atrophaeus spores and 
Escherichia coli in medical devices surfaces [9], and the best antimicro-
bial effect was seen when plasma was applied directly to the surface 
[10]. 
Among LTP’s recognized uses in biomedicine, some efforts have been 
made to assess its effects on biofilms, which is a dense and complex 
microbial community surrounded by an adhesive glue-like matrix that 
enhances resistance to adverse conditions and external stresses [11]. 
Biofilm organization is known to prevent disease eradication by con-
ventional antimicrobial therapy due to their poor penetration into the 
biofilm, in addition to the antimicrobial therapy adverse effects related 
to bacterial resistance and systemic toxicity. However, the antibacterial 
effects of LTP, which are intermediated by ROS, do not show to increase 
bacterial resistance when bacteria are continuously exposed to it. These 
findings indicate that LTP is potentially a good candidate for in vivo 
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antibiotic treatments [12–14]. 
Plasmas can reach greater gas-phase chemistry deprived of high gas 
temperatures [15,16]. It happens because plasmas display much higher 
electron energies than that of the ions and the neutral species. The en-
ergetic electrons go into a collision with the background gas, producing 
higher dissociation, excitation, and ionization levels. Since ions and 
neutrals continue quite cold, there is no contact thermal damage caused 
by the plasma. This feature supports plasma use as a treatment for 
heat-sensitive materials, for instance biological matter, cells, and tissues 
[17]. 
Currently, a large number of research-applied LTP have been 
developed. Overall, they can be identified as direct and indirect 
discharge, i.e. dielectric barrier discharge and atmospheric pressure 
plasma jet, respectively. Furthermore, few devices have been certified 
for medical use. Among them, kINPen®MED (INP Greifswald/neoplas 
tools GmbH, Greifswald, Germany), an atmospheric pressure plasma jet; 
and PlasmaDerm® VU-2010 (CINOGY Technologies GmbH, Duderstadt, 
Germany), a dielectric barrier discharge source, are both certified by 
MEDCERT, in Germany, under ISO 13485 [3]. Afterward, SteriPlas 
(Adtec Ltd., London, United Kingdom) has also been certified as a 
medical device, being employed as a therapy for chronic and acute 
wounds, in addition to the reduction of microbial load. However, 
considering different research groups use different devices, as well as 
modified therapies, the comparison among their findings is challenging. 
In fact, due to these differences, determining the long-term security and 
efficacy of plasma devices in a comparable and standardized way be-
comes complex. Many organizations have been created to certify tech-
nical standardization, including the German Institute for 
Standardization (DIN); The European Committee for Standardization 
(CEN); and the International Organization for Standardization (ISO) for 
plasma standardization [3]. 
Recently, the United States Food and Drug Administration (FDA) 
approved cold atmospheric plasma technology for use in a clinical trial 
for cancer patients. The technology was approved for a phase I clinical 
trial in 20 patients and is still under development. A multi-institute team 
established a pen-like electrosurgical scalpel that sprays a jet of LTP for 
2–7 min at residual cancerous cells or tissues [18]. The key feature is 
that the device only targets tumors, leaving contiguous tissue uninjured. 
These properties were shown by in vitro, in vivo, and FDA-approved 
compassionate use cases before the clinical trial [18]. 
The applications of plasmas in medicine have attracted interest in the 
medical research communities [11]. Plasma medicine applications 
include treatment of oral biofilm-related infections [12,13], treatment 
of wounds and skin diseases [19–21], assistance in cancer treatment 
[22–24], treatment of viruses infections (e.g. herpes simplex [25]); as 
well as, but not limited to, optimization of implants surfaces [26–28]. 
Each of those applications will be discussed in this review article (Fig. 1). 
2. Plasma medicine applications 
Table 1 contains information of plasma application, type of study 
and plasma sources of most of research papers discussed in this review. 
2.1. LTP therapy in oral biofilm-related diseases 
Microorganisms’ cells are displayed in two forms: planktonic, also 
called free-floating relatively independently; or attached to each other 
and to a host material. This second form can cause the development of a 
dense community of microorganisms surrounded by an adhesive matrix 
that, in general, sticks itself to a solid surface. This complex and well- 
protected community is called biofilm. Biofilms are usually present on 
solid substrates, but it can also be found in pores interacting with 
aqueous solutions, as well as floating films on liquid surfaces. Cells in a 
biofilm are known for closely interacting with each other inside its 
shielding milieu, showing different phenotypes when compared to the 
same species free-floating planktonic cells. One of the most remarkable 
characteristics of these cells, when organized as a biofilm, is their su-
perior resistance to unfavorable conditions and external stresses. Bio-
films are known as strong communities, being resilient to chemicals 
found in detergents and even to antibiotics that are known to affect 
planktonic cells. Hence, if not controlled, biofilms could characterize as 
significant health hazards in many situations. Furthermore, biofilms can 
cause damage to the surfaces they attach to, including corrosion, 
combining an economical cost in addition to their health risk [29,30]. 
Fig. 1. Plasmas produce electromagnetic radia-
tion, including ultra-violet (UV) radiation and 
light in the visible spectrum, and involves excited 
gas particles, charged ions, free electrons, free 
radicals, neutral reactive oxygen and nitrogen 
species (ROS/RNS), and molecule fragments. 
Plasma medicine applications include treatment 
of oral biofilm-related infections, treatment of 
wounds and skin diseases, assistance in cancer 
treatment, treatment of viruses’ infections, as 
well as optimization of implants surfaces. (For 
interpretation of the references to color in this 
figure legend, the reader is referred to the Web 
version of this article.)   
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Biofilms are known, for instance, to play a significant part in the 
pathogenesis of many oral diseases, one of them being oral candidiasis, 
which is an opportunistic infection of the oral cavity with a wide range 
of clinical signs and symptoms, for example, denture stomatitis, pseu-
domembranous candidiasis, erythematous candidiasis and angular 
cheilitis [31]. Infections initiated by Candida spp. are associated with 
biofilm formation, and oral yeast infections are mainly caused by 
Candida albicans [32]. Considering there are several challenges for 
chemical disinfection in dental practice, including the use of sodium 
hypochlorite for denture cleaning, the effects of plasma treatment as a 
physical method to disinfect C. albicans biofilms has been investigated. 
Plasma treatment significantly reduced the C. albicans colony forming 
units (CFU) compared to chemical disinfectants (chlorhexidine and so-
dium hypochlorite) [33]. Likewise, antimicrobial effects of LTP on 
biofilms of C. albicans and Staphylococcus aureus, and its safety on an in 
vitro reconstituted oral epithelium were evaluated [12]. Biofilms were 
submitted to LTP treatment for 1 min. Penicillin G and fluconazole were 
used as positive controls for S. aureus and C. albicans, respectively. All 
Table 1 
Plasma application, type of study and plasma sources of research papers dis-
cussed in the review.  
PLASMA 
APPLICATION 
TYPE OF STUDY PLASMA 
SOURCE 
REFERENCES 
ORAL BIOFILM 
C. albicans 
Staphylococcus aureus 
In vitro Argon-based plasma 
jet (kINPen®09, 
neoplas tools GmbH, 
Germany) 
[12] 
Enterococcus faecalis In vitro Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[36,37] 
Peri-implantitis 
microcosm biofilm 
In vitro Argon 1% Oxygen 
based plasma jet 
(kINPen®08, INP, 
Germany 
[45] 
Streptococcus mitis In vitro Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[46] 
Porphyromonas 
gingivalis 
In vitro Argon-based plasma 
jet (kINPen®09, 
neoplas tools GmbH, 
Germany) 
[13] 
WOUND AND SKIN DISEASES 
Porphyromonas 
aeruginosa 
In vitro Argon based or Argon 
1% Oxygen based 
plasma jet 
(kINPen®09, neoplas 
tools, GmbH, Germany 
[50] 
Staphylococcus 
epidermidis 
In vitro 
Chronically infected 
wounds 
In vivo (clinical) Argon-based 
microwave-driven 
plasma device 
(MicroPlaSter alpha 
and beta, ADTEC 
Plasma Technology Co. 
Ltd, Japan/UK) 
[51] 
Trichophyton rubrum, 
Trichophyton 
interdigitale, 
Microsporon canis, 
C. albicans 
In vitro Argon-based plasma 
jet (kINPen®09, 
neoplas tools GmbH, 
Germany) and 
Dielectric Barrier 
Discharge (DBD) 
plasma device 
[49] 
Severely contaminated 
wounds 
In vivo (clinical) Argon-based Maxium® 
electrosurgery unit 
with maxium® beamer 
and beam electrode 
(Gebrüder Martin 
GmbH  Co. KG) 
[19] 
Non-infected wounds In vivo (clinical) Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[52] 
Patients with wound 
healing disorder 
In vivo (clinical) Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[53] 
Mammalian cell lines 
related to wound 
healing 
In vitro Argon-based plasma 
jet (APPJ device) 
[20] 
Diabetic wounds In vivo (mice 
model) 
Helium-based plasma 
jet and plasma- 
activated medium 
(PAM) 
[21] 
CANCER THERAPY (DIRECT TREATMENT) 
Lung cancer cell lines In vitro/in vivo 
(mice model) 
Helium-based plasma 
jet (lab developed at 
George Washington 
University) 
[54] 
Murine melanoma cell 
lines (B16–F10) 
Bladder cancer tumor 
cells (SCaBER) 
Glioblastoma U87MG In vitro/in vivo 
(mice model) 
Floating Electrode (FE) 
– DBD plasma device 
[55]  
Table 1 (continued ) 
PLASMA 
APPLICATION 
TYPE OF STUDY PLASMA 
SOURCE 
REFERENCES 
Colorectal carcinoma 
HCT-116 
In vitro 
Murine neuroblastoma In vitro/in vivo 
(mice model) 
Helium-based plasma 
jet 
[56] 
Breast cancer tumor 
cell lines (4T1) 
In vitro/in vivo 
(mice model) 
Helium-based Micro 
(μ) Plasma Jet 
[57] 
Head and neck cancer 
cell lines 
In vitro Surface Micro 
Discharging (SMD) 
plasma device 
(MiniFlatPlaSter®) 
[22] 
Head and neck 
squamous cancer 
In vivo (clinical) Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[23] 
CANCER THERAPY (INDIRECT TREATMENT) 
Immune modulators, 
Intracellular ROS 
production inducers 
In vitro/in vivo Nanosecond pulsed 
dielectric barrier 
discharge (nsDBD) 
plasma 
Nonequilibrium 
atmospheric pressure 
Plasma (NEAPP) 
[63–66] 
[68–70] 
VIRUSES 
Influenza A and B In vitro Nitrogen-based plasma 
device (BLP-TES, NGK 
Insulators Ltd., 
Nagoya, Japan) 
[75] 
Respiratory syncytial 
virus (RSV) 
In vitro 
Human adenovirus 
(HAdV-4, -5, -20, 
-35, -37, -50) 
In vitro Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[77] 
Herpes simplex virus 
type 1 (HSV-1) 
In vitro Argon-based plasma 
jet (kINPen®MED, 
neoplas tools GmbH, 
Germany) 
[25] 
Herpes zoster In vivo (clinical) Argon-based 
microwave-driven 
plasma device 
(MicroPlaSter alpha 
and beta, ADTEC 
Plasma Technology Co. 
Ltd, Japan/UK) 
[79] 
IMPLANT SURFACES 
Surface modification 
and osseointegration 
In vivo (canine 
model) 
Argon-based plasma 
jet (kINPen®09, 
neoplas tools GmbH, 
Germany) 
[26] 
Wound healing and 
osseointegration 
In vivo (canine 
model) 
Argon-based plasma 
jet (kINPen 
[82]  
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biofilms treated with LTP showed substantial CFU decrease, change in 
morphology, and decreased viability when compared to control treat-
ments. Additionally, fluorescence microscopy revealed the occurrence 
of ROS in all biofilms treated with LTP. In the oral epithelium of negative 
control and plasma group cytotoxicity was low and viability was high. 
Moreover, histology did not exhibit signs of necrosis or important 
modification in the plasma-treated epithelium, and it was identified 
preservation of cell proliferation in the plasma-treated epithelium. 
Therefore, LTP showed to reduce single- and dual-species of C. albicans 
and S. aureus biofilms, with no toxic effects in the reconstituted oral 
epithelium [12]. 
Furthermore, decontamination of the root canal system is known to 
be of the highest relevance in the success or failure of root canal treat-
ment, even though complete sterility is unfeasible [34]. Currently, there 
is no other solution or material to replace the widespread use of sodium 
for root canal disinfection. However, much strength has been dedicated 
to complementing the effects of sodium hypochlorite [35], such as the 
use of LTP. A study compared the possibility of using an atmospheric 
pressure plasma jet for endodontic treatment and compared its antimi-
crobial efficacy with conventional irrigation solutions, such as chlor-
hexidine digluconate and sodium hypochlorite, against intracanal 
bacteria Enterococcus faecalis. Plasma jet reached greater microbial 
reduction when compared to chlorhexidine irrigation and a similar 
reduction compared to sodium hypochlorite [36]. 
Since LTP has shown promising results in disinfecting E. faecalis in 
root canals, a study analyzed the bactericidal efficiency of LTP in various 
depths of infected root dentin. Standardized human mandibular pre-
molars root canals were contaminated with E. faecalis and incubated for 
one week. The highest general logarithmic reduction factors were ach-
ieved from the combination of chlorhexidine with LTP, followed by LTP 
alone. Therefore, the adjuvant use of LTP might be beneficial in highly 
infected root canals to improved disinfection [37]. 
In addition to root canal and oral candidiasis, oral microbiota sub-
stantially affects biofilm formation on recently placed dental implants. It 
is well established that biofilm-induced inflammation around dental 
implants plays a dominant role in promoting osteoclast-mediated bone 
resorption and inhibiting bone formation, leading to net bone loss 
around implants [38]. This process is referred to as peri-implantitis, a 
bacteria-initiated infection that to date has no effective treatment [39, 
40]. Peri-implantitis is a significant oral health issue that can affect 
healthy and systemically compromised patients and may result in loss of 
dental implants [41,42]. As many as 45% of patients with dental im-
plants will develop peri-implantitis within a decade and a recent 
workshop hosted by the American Academy of Periodontology and the 
European Federation of Periodontology points to this significant prob-
lem [43,44]. Peri-implant infections, once established, are likely to 
progress and lead to implant loss. One of the reasons for the lack of 
success treating peri-implantitis is frequently that the instrumented 
implant surface and remaining microbial biofilm slow down or impede 
re-osseointegration. A human oral biofilm was formed on titanium discs 
and compared to the treatment with a brush only, 1% 
oxygen/argon-based plasma, or brushing combined with plasma to 
disrupt the biofilm. The controls were discs with no biofilm, autoclaved 
biofilm, or untreated biofilm. Afterward, human osteoblastic cell growth 
(MG-63) was analyzed after one and 24 h. Biofilm fragments present on 
the brush and plasma decreased osteoblastic cell development, while the 
brush  plasma provided a larger area of osteoblastic cells. Brush 
plasma was the only treatment in which 5-day cell growth was detected. 
Based on the results, combining brushing and LTP showed to be a po-
tential strategy for the treatment of peri-implantitis [45]. 
Since surface cleansing is known to be a challenge for the treatment 
of peri-implant infection, the bactericidal efficiency of tissue tolerable 
plasma was investigated on in vitro Streptococcus mitis biofilms formed on 
titanium dental implants. Confocal laser scanning microscopy (CLSM) 
and scanning electron microscopy (SEM) were used to analyze the bio-
films. One (1) % sodium hypochlorite was used to rinse the implants as 
the negative control, and as the positive control, implants were irradi-
ated for 60 s with a diode laser. Treatments were plasma application for 
60 or 120 s. Recovered colonies were determined by CFU counting. 
Further, implants were observed by fluorescence microscopy. The CFU 
counts on the groups treated with plasma for 60 or 120 s were expres-
sively inferior to the control, and no differences between 60 and 120 s of 
plasma treatment were detected. Before treatment, CLSM and SEM 
detected attached bacteria; however, fluorescence microscopy showed 
that plasma treatment on titanium surfaces exhibit a higher number of 
dead cells when compared to the controls in the post-treatment [46]. 
The development of periodontal and peri-implant diseases has been 
associated with several oral anaerobic-restrict species in the subgingival 
environment, including black-pigmented Porphyromonas species, being 
Porphyromonas gingivalis and Fusobacterium nucleatum the main patho-
gens of this type of infection. Therefore, LTP effects were determined on 
an anaerobic biofilm of P. gingivalis and on how it affects an in vitro 
reconstituted gingival epithelium tissue. LTP treatment for 1 and 3 min 
was applied to a P. gingivalis biofilm grown on titanium discs and to the 
reconstituted gingival epithelium. The LTP treatments were compared 
to 0.2% chlorhexidine application for 1 min, with the argon gas-only 
application for 3 min, and with no treatment application (negative 
control). LTP application for 1 and 3 min significantly decreased the 
CFU/mL when compared to the negative control, although they were not 
as effective as chlorhexidine application for 1 min. As for the gingival 
epithelium, cytotoxicity was low and viability was high for all the 
groups. Minor cell damage was observed in the morphologic analysis of 
gingival epithelium for the plasma groups. Thus, LTP is potentially an 
effective treatment aiming to reduce P. gingivalis biofilm on implant 
surfaces and is safe for the gingival epithelium. Additionally, it may be 
related to cell repair [13]. 
The application of LTP for the treatment of oral infections, mainly to 
remove biofilms, is a promising field of future application. The unique 
characteristics of LTP have opened a new era in dental care. It has shown 
promising results in oral biofilm-related disease control. Plasma dental 
treatments are painless and drill-less, thereby making them patient- 
friendly [47]. However, more studies need to be conducted for the 
clarity in the mechanism of action and its varied application in the 
dental field. 
2.2. LTP to treat wounds and skin diseases 
There is evidence showing LTP is an innovative antimicrobial ther-
apy, presenting as an alternative to traditional antibiotic treatments, as 
well as its beneficial action on wound healing, making it a promising 
instrument for biomedical uses, including, but not limited to, the man-
agement of infections [48]. A large number of studies have described the 
lethal effects of LTP on microorganisms such as bacteria and fungi, 
showing its potential as an effective apparatus for disinfection. Skin and 
nail fungal infections, chronic wounds, and multidrug-resistant patho-
gens like S. aureus (MRSA) are critical therapeutic and economic prob-
lems. Therefore, novel therapies for these conditions are highly 
necessary. The challenge of global rising microbial resistance distresses, 
comprising various pathogens including methicillin-resistant MRSA, 
vancomycin-resistant enterococci, and gram-negative species producing 
beta-lactam hydrolyzing enzymes (extended-spectrum β-lactamases), 
create the need for alternative antimicrobial treatments. Besides being 
site-specific, LTP therapy grants a very different mechanism of action 
when contrasted to traditional antimicrobials, and might function as a 
substitute for common antibiotic and antiseptic therapies [49]. 
Knowing that microbial biofilms make wound healing difficult and 
the antiseptics are not always effective, LTPs from different gases, argon- 
based and an argon/oxygen-mixture-based plasma, were applied to 
determine their efficacy on the treatment of biofilms of Pseudomonas 
aeruginosa and Staphylococcus epidermidis formed in vitro. The antiseptic 
chlorhexidine digluconate was used as the positive control. Biofilms 
were exposed to LTP for 30, 60, 150, or 300 s and the control group was 
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treated with 0.1% chlorhexidine solution for 600 s. Biofilms were then 
dispersed and the recovered CFUs were used to measure inactivation. 
There was a significant antimicrobial effect when LTP treatment was 
compared to the untreated control and it was at least as effective as the 
treatment with chlorhexidine, or even better, depending on the gas, the 
bacterial strain, and the exposure time [50]. 
In a prospective randomized controlled study, twenty-four patients 
with chronically infected wounds received daily treatment with 2 min of 
argon-based LTP, in addition to the standard wound care. A significant 
decrease in bacterial load was seen in wounds that were treated with 
plasma, independent on the bacterial species. In addition, the safety of 
treatment with argon-based LTP devices has been shown, as well as 
being painless and effective to reduce bacterial load in chronic wounds 
[51]. Furthermore, plasma treatment was shown to be effective in 
damaging microbial, fungal, and parasitic dermal strains and species 
including E. coli, P. aeruginosa, Klebsiella spp., S. aureus, hemolyzing 
Lancefield Streptococci (group A and B), Proteus group (Proteus mir-
abilis, Proteus vulgaris), Acinetobacter spp., Stenotrophomonas spp., 
E. faecalis, C. albicans, and S. epidermidis. In vitro, more than 90% of 
bacteria Trichophyton rubrum, Trichophyton interdigitale, Microsporon 
canis, and yeast C. albicans were killed by 30 s LTP exposure, with no 
isolate exhibiting resistance [49]. 
How LTP affects multidrug-resistant pathogens was evaluated con-
cerning non-multidrug-resistant-pathogens in chronic wounds. Eleven 
patients with 18 severely contaminated wounds were submitted to 
treatment with an argon-based LTP for 10 s/cm2 in a single session. It 
was observed that a single treatment reduced multidrug-resistant mi-
croorganisms in all wounds. As proof of principle, it was shown that 
argon-based low-temperature plasma functions as a strong treatment 
modality that limited multidrug microbial colonization [19]. 
Plasma has also been applied in the healing of non-infected, acute 
(iatrogenic) wounds. For instance, in a clinical study with five in-
dividuals, 20 laser lesions were treated with argon-based LTP for 10 s, 
30 s, or 3 applications of 10 s, compared to the untreated control. Scar 
development was observed for 10 days, six months, and one year. In the 
initial stages of healing, LTP appeared to maintain the inflammation 
required during tissue recovery. In advanced stages, LTP displayed su-
perior effects regarding evading post-traumatic skin conditions. Plasma 
treatment exhibited excellent aesthetics throughout scar establishment 
and no precancerous skin features happened up to one-year [52]. A 
proof of concept study assessed the clinical effect of LTP exposure in 
patients presenting wound healing disorders and that had exposed 
brachial tendons of the radial forearm. In this prospective study, four 
patients who had suffered radial forearm free flap procedures and faced 
wound healing disturbance, which ended in exposed flexor tendons, 
were included. Besides routine wound treatment, all sites were exposed 
to LTP, which resulted in total wound closure. For all the involved 
subjects, total wound repair, which was measured by the lack of tendon 
exposure, was detected within a mean exposure time of 10.1 weeks. 
Unwanted side effects were not perceived, and there was no inflam-
mation or infection. Therefore, LTP may present a consistent conserva-
tive treatment route for complex wound healing disorders [53]. 
LTP has shown to be promising adjuvant in wound healing, even 
though its mechanism remains poorly understood. Aiming to understand 
the effects of LTP on mammalian cells, an argon-based LTP jet was 
applied to treat in vitro cultured L929 murine fibroblasts, as well as 
BALB/c mice skin wounds. The study showed that when fibroblasts were 
treated with LTP for 15 s, there was a significant increase in cell pro-
liferation, secretion of epidermal growth factor, and transforming 
growth factor-βi, production of intracellular ROS, and the percentage of 
cells in S phase, protein expression of phosphorylated p65 and cyclinD1. 
However, there was a reduction in protein expression of inhibitor kappa 
B. The in vitro study showed that LTP exposure for 30 s increased the 
number of fibroblasts and the ability of collagen synthesis, while the 
exposure for 50 s led to opposed outcomes. This outcome indicates that 
LTP stimulates wound healing related fibroblast proliferation by 
inducing the production of ROS, upregulating phosphorylated p65 
expression, downregulating inhibitor kappa B expression, and activating 
the NF-κB signaling pathway, leading to an altered cell cycle progres-
sion, demonstrated by the augmented DNA synthesis in S phase [20]. 
As plasma medicine’s applications continue to expand and consid-
ering its positive impact in wound healing, a recent in vitro and in vivo 
study was conducted to evaluate the LTP’s efficacy and safety as a 
treatment for diabetic wounds. Eight-week-old male db/db mice and 
C57BL mice were treated with LTP for 90 s and LTP for 180 s, as well as 
helium gas (flow-control group). Mice were treated and monitored for 
2 weeks. Blood samples and skin samples from around the wound were 
collected. After 14 days of treatment, LTP stimulated the healing of 
diabetic wounds, which presented closure rates significantly higher in 
the groups treated with LTP groups (90 and 180 s) in relation to the flow- 
control group. IL-6, tumor necrosis factor-α, inducible nitric oxide syn-
thase, and superoxide dismutase protein expressions in two LTP groups 
were significantly reduced, when compared with the control group. 
However, vascular endothelial growth factor and transforming growth 
factor-β protein expression groups significantly increased in the two 
groups treated with LTP. Scratch wound-healing in vitro assays demon-
strated that LTP might effectively guarantee healing in 3 min exposure. 
Moreover, there was no difference in normal skin histological observa-
tions, as well as no difference in the levels of serum alanine trans-
aminase, aspartate aminotransferase, blood urea nitrogen, creatinine, 
and white blood cells amongst the LTP and control groups. Hence, daily 
3 min LTP treatment showed to improve wound healing in diabetic mice 
by defeating inflammation, reducing oxidative stress, and increasing 
angiogenesis, engaging various proteins signaling, and LTP therapy 
showed to be safe for the liver and kidney [21]. 
LTP has been presented as a favorable and reasonable therapy for a 
wide range of diseases, however, more studies in the plasma medicine 
field are needed to further investigate the clinical therapeutic potential 
of LTP and to entirely comprehend its modes of action. In general, 
plasma medicine research is growing and providing emergent proof for 
the use of LTP as a treatment choice for various wounds and skin 
diseases. 
2.3. LTP use for cancer therapy 
LTP might have the ability of delivering ROS directly into tissues, 
demonstrating to be an innovative modality for targeted, or direct 
cancer therapy. Both in vitro and in vivo studies using lung cancer cell 
lines, murine melanoma cells B16–F10, and subcutaneous bladder can-
cer tumors (SCaBER) cells demonstrated that LTP selectively killed 
cancer cells with no damage to normal cells; moreover, LTP application 
expressively reduced tumor size in vivo. Furthermore, when LTP was 
applied ROS metabolism and oxidative stress response genes expression 
were increased [54]. 
The in vitro antitumor activity of LTP was also evaluated on two 
human cancer cell lines (glioblastoma U87MG and colorectal carcinoma 
HCT-116). LTP produced a great quantity of ROS, damaging the DNA 
damages, which caused a multiphase cell cycle arrest followed by 
apoptosis induction. Moreover, in vivo tests on U87MG bearing mice 
demonstrated that LTP stimulated a decrease of bioluminescence and 
tumor volume when evaluated against non-treated mice. Apoptosis in-
duction as well as accumulation of cells in the S phase of the cell cycle 
were also noticed, indicating a tumor proliferation arrest could have 
happened [55]. 
Cold plasma was also studied in vitro and in vivo murine model for 
treating neuroblastoma. Mouse neuroblastoma cultures were exposed to 
LTP for 0, 30, 60, and 120 s and immediately examined for apoptotic and 
metabolic activity, as well as 24 h and 48 h post-treatment. Tumors 
measuring 5 mm diameter were subjected to a single transdermal LTP 
treatment. Then, tumor volume and mouse survival were determined. 
Plasma treatment reduced metabolic activity, induced apoptosis, and 
reduced viability of cancer cells, proportionally to both exposure and 
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post-treatment time. In vivo, tumors were also subjected to a single 
treatment, which resulted in eventually reduced tumor growth. Addi-
tionally, survival almost doubled. Hence, neuroblastoma showed to be 
susceptible to plasma treatment on in vitro and in an in vivo mouse model 
of the established tumors [56]. 
Another study evaluated how micron-sized non-thermal atmospheric 
pressure plasma applied inside the animal body affects breast cancer 
tumor. The μ-plasma jet is comprised of micron-sized hollow tube 
wherein pure helium gas is ionized by high voltage (4 kV) and high 
frequency (6 kHz). The plasma killing efficacy on cancer cells was pri-
marily determined by treating 4T1 cells and verifying viability using 
flow cytometry and cell cycle investigation. For examination of the in 
vivo plasma jet effects, BALB/c mice were inoculated with 4T1 cell lines 
and then the cells were treated subcutaneously for 3 min. The outcomes 
indicated that μ-plasma efficacy in suppressing tumor growth is similar 
to that of standard chemotherapy medication. Furthermore, data 
showed that μ-plasma produces apoptosis in the tumor tissue and en-
hances the ratio of the apoptotic to anti-apoptotic protein expression 
[57]. 
Clinical data shows that head and neck squamous cell cancer takes 
the position of 7th among the most frequent cancers worldwide [58]. 
Regardless of the progress of finding new therapies, including mono-
clonal antibodies, prognosis remains the same for the last decades [59]. 
In another study, the efficiency of a surface micro discharging plasma 
device on two head and neck cancer cell lines was evaluated. Effects on 
cell viability, DNA fragmentation, and apoptosis were tested using MTT 
assay, alkaline micro-gel electrophoresis (comet assay) and 
Annexin-V/PI staining. MTT assay demonstrated plasma significantly 
reduced cell viability for all treatment times (30, 60, 90, 120, and 180 s). 
Comet assay indicated dose-dependent high DNA fragmentation as one 
of the key players in the anti-cancer effects of LTP. In contrast, 
annexin-V/PI staining showed apoptosis induction in plasma-treated 
head and neck squamous cell cancer lines, but no significant 
dose-response was observed [22]. 
Afterward, in order to determine the clinical application of LTP on 
head and neck squamous cell cancer, patients (n  12) presenting 
advanced head and neck cancer and infected ulcerations received local 
LTP application and subsequent palliative therapy. Four of those pa-
tients presented tumor surface response after 2 weeks of intervention. 
The tumor surface reaction was stated as a flat area with vascular 
stimulation (type 1) or a contraction of tumor ulceration rims devel-
oping recesses covered with scabs, in each case delimited by tumor 
tissue in evident progress (type 2). Meanwhile, nine patients with 
similar cancer type were subjected to LTP treatment before radical 
tumor resection and specimens collected from the tumors were evalu-
ated for apoptotic cells. Apoptotic cells were measurable and appeared 
more often in tissue areas that were treated with LTP than in untreated 
areas. Remarkably, no patient showed signs of a higher or stimulated 
tumor growth due to the effect of LTP [23]. 
Another clinical study evaluated the effects of LTP treatment on six 
patients with locally advanced head and neck cancers. Two of those 
patients presented a remarkably positive response to the treatment with 
subsequent clear tumor reduction. Whereas the tumor in one of these 
patients began to regrow leading to the patient’s death, the other patient 
continued receiving treatment, targeting for total remission. Side effects 
were not detected in two of the patients, while four patients experienced 
fatigue and dry mouth. Five of the patients had a decrease in odor, 
perhaps because of disinfection, and four patients presented lower 
requirement for pain medication. From the six patients at the beginning 
of the study, five passed away after 1–12 months, which was shown to be 
unrelated to the LTP application. The role of ROS/RNS, myeloid cells 
and the immunogenic cell death model of cancer treatment as potential 
mechanisms of action of LTP treatment was substantially discussed [24]. 
Besides LTP application for direct cancer therapy, LTP can also be 
applied for indirect cancer treatment. Indirect treatments comprise 
plasma-assisted cancer immunotherapy and plasma-activated medium 
(PAM) therapy [60–62]. Researchers have suggested the use of plasmas 
as immune modulators for cancer treatment [61,62]. Radiation and 
some chemotherapeutic medications rise immunogenicity by triggering 
immunogenic cell death (ICD). Damaged or stressed cancer cells have 
danger indicator, which are identified as damage-associated molecular 
pattern (DAMP) molecules. Cancer cells typically induce immunosup-
pression, which is ICD-associated. DAMP molecules can reactivate 
anti-cancer immunity by activating dendritic cell maturation and anti-
gen presentation. High-mobility group box 1, ATP, and calreticulin 
(CRT) are well-known DAMP molecules that are retained inside the cell 
in the healthy state and released only in response to stress or cell 
damage. Studies observed that non-thermal plasma treatment induces 
ICD and stimulates macrophages [63–66]. In the plasma-assisted cancer 
immunotherapy, LTP treatment stimulates extracellular ATP secretion 
and increases cell death through ICD-mediated macrophage stimulation. 
Plasma-generated ROS are main effectors of ICD. LTP produces surface 
exposure of CRT, and N-acetyl cysteine, which is an ROS scavenger, 
reduces the externalization of CRT. These results propose that intracel-
lular ROS are responsible for plasma-induced CRT production. Tumor 
necrosis factor–alpha released from plasma-activated macrophages in-
duces tumor cell death [67]. PAM is as a type of cancer chemotherapy, 
which, in most cases, induces intracellular ROS production following 
apoptosis of cancer cells [62]. Intraperitoneal injection of 
PAM/plasma-activated Ringer’s lactate repressed the metastasis of 
gastric, pancreatic and ovarian tumors in a mouse examining peritoneal 
metastasis [68–70]. 
However, while LTP has already achieved standard medical care 
status for wound treatment, only primary data for its potential as a 
therapy in oncology are available [3]. No resistance to LTP treatment 
has been reported yet, although the clinical use of LTP requires the 
improvement of standardized consistent protocols to relate the findings 
among upcoming clinical trials. Further research is also necessary to 
define the most effective type of plasma for each variety of cancer [71]. 
Yet, based on the reported data, LTP remains a promising therapy for 
cancer treatment. 
2.4. LTP to treat viruses’ infections 
In addition to prior discussed properties, including the fact LTP ef-
fects decreasing bacterial load in chronic wounds, possibly promoting 
wound healing; only a few studies have assessed LTP effects on viruses’ 
infections. Viruses may be transferred straight from one infected person 
to another, or indirectly through contaminated intermediates, for 
example, surfaces, objects, food, water, and air. Transmission through 
contaminated surfaces and aerosols has shown to be of remarkable 
relevance in the COVID-19 pandemic, which is caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) [72]. The viral capsid 
is the initial interaction with a host, and for successful recognition of a 
virus by the host cell receptors, it is essential that their external 
arrangement is relatively undamaged. When in the host cells, the viral 
genome takes control of the replication process. Consequently, these two 
factors are the most significant ones for the assessment of virus inacti-
vation [73]. 
Management of the respiratory viruses’ influenza A and B [74] and 
respiratory syncytial virus (RSV) [75] have only been executed with the 
pulsed high-voltage LTP supply. RSV is the most common causal agent of 
lower respiratory tract infections in infants, being one of the most sig-
nificant viruses in pediatric patients, mainly because it proliferates 
simply through contact with contaminated surfaces [76]. Even if 5 min 
LTP application totally inactivated RSV on et al., glass [75], a portable 
and more convenient plasma arrangement would be desirable for 
effective disinfection of, for example, hospital surfaces, whereas the 
high-voltage plasma devices would be applied only for small objects and 
tools disinfection (Filipic et al., 2020). Some respiratory viruses are also 
known to persist stably as aerosols for extended intervals of time, 
including SARS-CoV-2, and with the aim of diminishing their spread, it 
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is essential to decontaminate the air, in addition to the surface areas 
[73]. 
Besides respiratory viruses’, the effects of LTP therapy on human 
adenoviruses (HAdV) were reported. Adenoviruses involve numerous 
agents affecting reptiles, birds, fishes, and mammals. There are over 70 
categories of HAdV and they can be genetically separated into seven 
very distinct species (A to G). HAdVs are widespread pathogens known 
to cause several disease symptoms, dependent on the type. They are 
typically not deadly and can be self-limiting in immunocompetent pa-
tients. These viruses are also well known to affect the upper and lower 
respiratory tracts and the digestive and urinary tracts, as well as dis-
turbing internal organs, aggravate asthmatic and chronic obstructive 
pulmonary conditions, cause highly infectious follicular epidemic 
keratoconjunctivitis or being fatal in immunocompromised patients 
[76]. Unfortunately, there is a deficiency of specific anti-adenovirus 
therapy available. To investigate antiviral properties of LTP, human 
adenovirus types resultant from different species (HAdV   4,   5,   20, 
  35,   37,   50) were purified and tagged with luciferase. They were 
then treated with distinct exposures to LTP (no treatment, 30 s, 60 s, 90 
s, 120 s, and 150 s). During LTP application, a 15 mm distance from the 
plasma tip to the medium surface was maintained. After LTP applica-
tion, the solution containing the virus was transferred to eukaryotic cells 
and luciferase expression levels were used to determine the viral load. 
Through LTP treatment, HAdV-5 and HAdV-37 adenovirus driven 
luciferase expression straight associated with adenovirus transduction 
efficiencies were lowered. LTP application had no effect on luciferase 
expression levels for HAdV-4 and HAdV-50 and an increasing effect on 
luciferase expression levels for HAdV-20 and HAdV-35 was observed. 
These data show LTP has a type-dependent outcome on adenoviruses 
and, according to the reported data, it can increase infectivity for certain 
adenovirus types. Thus, LTP might be a suitable choice as an antiviral 
treatment, in a virus-type dependent behavior, but further studies 
should focus on the processes behind this occurrence [77]. 
Recently, LTP was tested as a suitable therapy for herpes simplex 
virus type 1 (HSV-1). HSV-1 often expresses as recurrent herpes labialis, 
however, it is related to cases of encephalitis, conjunctivitis, or herpes 
neonatorum as a perinatal disease as well. HSV-1 encoding the reporter 
gene GFP was reproduced. HSV-1 was gradually exposed to LTP; with 
exposure times ranging from 0 to 150 s. The positive control was the 
antiviral drug acyclovir. After LTP exposure, the virus suspension was 
transferred to a standard HSV research cell line (Vero cells), as well as to 
neuroblastoma cell line SH-SY5Y as a neuronal infection model. The 
outcomes revealed that LTP had an insignificant antiviral effect on HSV- 
1 in both Vero- and SH-SY5Y cells at a high dose. Nevertheless, lowering 
the viral load to 100-fold reduced the number of internalized HSV-1 
genomes 3 h post-infection for LTP-exposed viruses. This change was 
less perceptible concerning GFP expression levels 24 h after infection, 
which was in strong divergence to the acyclovir-treated (positive con-
trol), in which the viral load decreased from 95 to 25%. Briefly, a slight 
but measurable antiviral effect of LTP on HSV-1 was observed [25]. 
Herpes zoster virus was also studied in regards to LTP therapy. 
Herpes zoster is a severe aching infectious skin condition that happens 
because of the varicella-zoster virus reactivation, with a growing inci-
dence in the elderly population [78]. Severe therapy for pain is typically 
necessary and post-herpetic neuralgia demanding continuing analgesia 
is a common problem. The effects of LTP treatments for herpes zoster 
was evaluated for pain reduction, healing rates, as well as safety. In a 
prospective randomized placebo-controlled phase II study, 37 herpes 
zoster patients were treated daily (weekdays) with 5 min of argon-based 
LTP (active) or 5 min of argon gas (flow-control, placebo), along with a 
standard therapy regimen. The visual analog scale was used to evaluate 
pain before and after treatment with LTP or placebo. Three clinicians 
evaluated digital images of lesions, blinded, and independently, in 
relation to vesicles, erythema, and general impression. Examination 
showed in LTP-treated patients presented a significantly greater reduc-
tion in pain over the treatment course when compared to controls, as 
well as an expressively superior median pain reduction immediately 
after each treatment. Plasma treatment pointed to faster clinical 
improvement in the first 1–2 days. Therefore, daily 5 min treatments 
with argon-based LTP was effective, painless, and safe, enhancing initial 
healing and decreasing severe pain in herpes zoster lesions [79]. 
The main agreement among the different studies up to the present 
time is that the ROS and/or RNS production is the main attribute of LTP, 
which affects viral inactivation, while UV radiation and temperature 
changes continue as minor contributors or have no effect whatsoever 
[73]. Studies on how LTP affects viruses are unique, considering that the 
specific plasma sources for each study are different (for example, 
dielectric barrier discharge, plasma μjet), with different characteristics 
(i.e. power, type of gas applied and exposure time). Moreover, the 
studies contend with the treatment of diverse liquid volumes or types of 
liquids, different substrates, as well as distinct viruses (surrogates of 
human viruses, human, animal, and plant viruses). Such a varied range 
makes a straight comparison of these studies very difficult, making it 
challenging to define the mechanistic assumptions or any general 
inactivation considerations [73]. Up to now, studies evaluating the ef-
fect of LTP on viruses’ infections are scarce, mostly when compared to 
other diseases, and little is known about the mechanism of the 
LTP-mediated antiviral action, therefore, further studies with viruses 
should be performed. 
2.5. LTP to optimize implant surfaces 
As a complementary medical application, LTP can be used to prime 
or improve surfaces to turn them medically biocompatible, such as 
functionalization of implant surfaces. Osseointegration is the direct 
organizational adaptation of bone to the implant [80], being a topic of 
distinct relevance to orthopedic surgeons and dentists. In arthroplasty, 
for instance, surrounding the prosthesis; in trauma, for example, sur-
rounding screws, and in dentistry, around dental implants. Bone 
anchorage on the implant surface can affect whether the reconstructive 
surgery will succeed and fail, and surface alterations may enhance the 
osseointegration of implants [28]. Since it has been established that 
moderately rough surfaces perform better than turned surfaces [84], 
current research is aiming at further alterations targeting a possible 
increase in the bioactivity of the implant. Therefore, some of the 
contemporary studies have shifted to chemically change slightly rough 
surfaces, which have been implied to create coactive effects. Moreover, 
the surface energy is an additional relevant factor participating in the 
regulation of osteogenesis [81]. 
Aiming to study the effects of LTP on rough titanium surface dental 
implants treated or not with argon-based LTP were investigated in an in 
vivo canine model. The surface energy and chemistry were character-
ized, showing peaks of titanium, calcium, and oxygen for both surfaces, 
and a 300% improvement in osseointegration was achieved for argon- 
based LTP treated titanium surfaces when compared to controls after 
three weeks [26]. However, a considerably slighter size effect of 
approximately 80% was detected for the argon-based LTP calcium 
phosphate surfaces relative to their untreated equivalents at the same 
implantation time [27]. Concerning physicochemical characterization, 
both studies showed the enhance in surface energy was more significant 
for the titanium surfaces when compared to the calcium phosphate 
surfaces, and those relative disparities when argon-based LTP treated 
and untreated surfaces were compared are the hypothetical cause for the 
relative changes in osseointegration. 
Considering the beneficial results obtained with LTP in dental im-
plants, the osseointegration properties of plasma surface treatment for 
implants were assessed, in another study, replacing argon for com-
pressed air as the gas source [28]. Physicochemical characterization to 
evaluate topography, surface energy, and chemical composition was 
performed. Reduced surface levels of carbon and enhanced titanium and 
oxygen for titanium surfaces, as well as increased calcium and oxygen 
for calcium phosphate surfaces were reported. A significant increase in 
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bone-to-implant contact for atmospheric LTP-treated textured titanium 
surfaces at 6 weeks was observed, but not at three weeks or for calcium 
phosphate surfaces. However, no significant differences for bone area 
fraction occupancy between treated and untreated surfaces for any 
material at any time point were seen. These results indicate that 
air-based LTP surface treatment might increase osseointegration of 
textured titanium surfaces but not calcium phosphate surfaces [28]. 
Compared with earlier researches, both physicochemical and in vivo 
results showed that air-based LTP treatment enhanced surface energy 
and assisted earlier osseointegration compared with controls, even 
though the observed increases were not as important as the ones 
resulting from the treatment with argon-gas. Nevertheless, further 
studies optimizing atmospheric pressure plasma parameters and appli-
cations are necessary [28]. 
A recent in vivo study determined how plasma surface conditioning 
interferes with early wound healing and osseointegration. Sixteen dental 
implants with sandblasted and acid-etched surfaces were treated with 
LTP before insertion in the frontal bone of four miniature pigs. Bone 
metabolism was labeled by sequential fluorescence labeling adminis-
tration, and eight weeks later, bone blocks were collected for radiolog-
ical, histological, and histomorphometrically assessment. According to 
the findings, plasma treatment showed to have no effect on the 
morphology of the implant surface. However, groups treated with LTP 
exhibited increased bone-to-implant contact ratio, inter-thread, and 
peri-implant bone density compared to the controls. Interestingly, newly 
formed bone presented chronological and consistent mineralization, and 
no undesirable peri-implant side effects were present [82]. 
In fact, research on the application of LTP on implant surfaces has 
been shown to modify the surface elemental chemistry, resulting in 
superior biomechanical fixation and bone formation. However, further 
studies in prospective clinical trials are needed to substantiate these 
findings. 
3. Conclusion 
Plasma medicine applications have been emerging in the last years 
and can potentially lead to a novel, site-specific, and effective therapy 
for numerous diseases. Among them, employing LTP for the treatment of 
oral infections, mainly to remove biofilms, is a promising field. Advan-
tages of LTP over traditional antimicrobial treatments are that LTP can 
be utilized for site-specific treatment; it provides an almost immediate 
(seconds) bactericidal response; antimicrobial resistance is less likely to 
appear because of LTP’s multiple mechanisms of action and diversity of 
active agents [48]; there are minimal side effects [83]. However, 
regardless of intense research effort through the last years, there is a lack 
of data for the clinical application of LTP in dentistry to date. In contrast, 
plasma medicine achieved standard therapeutic status for wound 
treatment [3] and, recently, the technology was approved for an FDA 
phase I clinical trial [18]. 
Research is increasing and providing emergent proof for the use of 
LTP as a treatment alternative for diverse wounds and skin diseases, but 
more studies are necessary to further explore to entirely comprehend its 
mechanisms of action. In terms of LTP’s effects in oncology, only pre-
liminary data are available, therefore, further studies using plasma 
different types of cancer are encouraged. Furthermore, to date, studies 
evaluating the effect of LTP on viruses are scarce, and little is known 
about the mechanism of the LTP-mediated antiviral action. Therefore, 
future studies using plasma to control viruses’ infections must be per-
formed, considering the promising results it has been showing in this 
field. Research on the application of atmospheric plasma on implant 
surfaces has been shown to modify the surface elemental chemistry, 
causing higher biomechanical fixation and bone formation. However, 
additional research in prospective clinical trials is still needed. 
What makes LTP therapy unique, though, is that LTP generators are 
small enough for safe and portable operation in clinical settings, having 
target-specific therapeutic effects, yet providing sufficient energy to 
impart meaningful alteration to biomaterials surfaces. Hence, LTP 
technology has been recently recognized as a powerful tool for 
biomedicine, considering its diverse plethora of therapeutic benefits. 
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